CagriSema Research for Obesity
An evidence-based overview of research examining CagriSema in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
CagriSema has been evaluated in Phase 3 REDEFINE trials for chronic weight management. REDEFINE-1 demonstrated 22.7% weight loss at 68 weeks in adults with obesity, with 60% achieving >=20% weight loss. This represents the highest weight loss efficacy demonstrated in pivotal trials for any anti-obesity medication to date.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CagriSema may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.